FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Tevogen Bio Holdings Inc. Stock AnalysisComprehensive stock analysis for Tevogen Bio Holdings Inc. (TVGN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTVGN
TVGN
Tevogen Bio Holdings Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TVGN
Home🔹Stocks🔹Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

FRC Coverage
TVGN•NASDAQ

Tevogen Bio Holdings Inc.

FRC Coverage
TVGN•NASDAQ
Sentiment

Your view on TVGN

Sentiment
Your view
TVGN
Tevogen Bio Holdings Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TVGN
Company Overview

Overview

What the company does, where it operates, and who runs it.

*Tevogen Bio Holdings Inc. has paid FRC a fee for research coverage and distribution of reports.

About Tevogen Bio Holdings Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Ryan H. Saadi M.P.H,
Headquarters
15 Independence Boulevard Suite #410, Warren, NJ, US
Industry
Biotechnology
Sector
Healthcare
CEO
Ryan H. Saadi M.P.H,
Headquarters
15 Independence Boulevard Suite #410, Warren, NJ, US
Description

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

FRC Research
Buy
Fair Value Estimate
US$4.20

Fast Tracking a Potential Breakthrough for Treating Viral Infections and Cancer

Report · Jun 17, 2024

Sign in to view

FRC Research
Buy
Fair Value Estimate
US$4.20

Fast Tracking a Potential Breakthrough for Treating Viral Infections and Cancer

Report · Jun 17, 2024

Sign in to view

Infographics

Visual summary of the business at a glance.

FRC Research

Research Reports

FRC analyst coverage and recommendations.

Past Reports

Historical coverage archive.

Analyst Notes

Ongoing commentary and updates from FRC analysts.

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News